Devyser Diagnostics AB (publ) (DVYSR.ST)
Devyser Diagnostics AB (publ) operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Årsta, AB, SE. The stock last traded at $51.70, down 1.15% on the session, giving a market capitalisation of $861.0M. Its beta of 0.78 implies it has historically moved less than the broad market.
Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products are crucial for genetic analysis in key medical areas, including hereditary diseases, oncology, and post-transplantation monitoring. Devyser offers a broad array of diagnostic tools, covering applications such as post-transplant management, thalassemia screening, and the detection of various cancers like breast, colorectal, and ovarian. Their portfolio also extends to non-invasive fetal RHD screening, diagnostics for inherited conditions, cystic fibrosis, cardiovascular issues, male infertility, and rapid aneuploidy analysis, complemented by essential accessories. These solutions are utilized for diverse purposes, from diagnosing genetic disorders and guiding targeted cancer treatments to ensuring thorough follow-up care for transplant patients. Furthermore, Devyser provides specialized software programs, including Amplicon Suite and Advyser, which facilitate the processing, analysis, and interpretation of test results, enabling efficient marker screening and patient sample tracking. The company's operations span Sweden, the broader European market, the Middle East, Africa, North and South America, and Asia.
Devyser Diagnostics AB (publ) is most often compared with the following Healthcare names: